Occentis is a drug discovery and development company, focusing on Autism, Alcohol and Opioid addiction and Pain.
Occentis is a drug discovery and development company, focusing on mental health, with a groundbreaking approach backed by over two decades of extensive research conducted at the renowned French National Center for Scientific Research (CNRS) under the guidance of Professor Marcel Hibert, a distinguished figure in medicinal chemistry. Our mission is to revolutionise the treatment landscape for neuropsychiatric and neurobehavioral conditions, addressing significant unmet needs in therapeutic areas such as Autism, Alcohol and Opioid addiction, Pain and other conditions. In close collaboration with Conectus, a leading technology transfer and innovation organization working with the CNRS, Occentis has exclusively licensed this remarkable research. Conectus, known for its expertise in bridging the gap between academia and industry, played a pivotal role in this partnership. Together with the CNRS and Professor HIBERT, Occentis is aiming to address critical unmet needs in mental health.
Occentis Pharmaceuticals - Pioneering innovative drug development in the fields of mental health, neuroscience, and addiction treatment.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
SATT Ouest Valorisation Research, Startup accelerator & VC, Research Services | SATT Ouest Valorisation Research, Startup accelerator & VC, Research Services | Other 30 Jun 2024 | | |
Réseau SATT | Other 16 Jul 2024 | | ||
SATT CONECTUS Research, Research Services | SATT CONECTUS Research, Research Services | Other 27 Sep 2024 | |